|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00458640 |
Purpose
RATIONALE: Gathering information about patients with central nervous system tumors over time may help doctors learn more about the disease and find better methods of treatment and on-going care.
PURPOSE: This natural history study is collecting disease-related health information over time from patients with central nervous system tumors being evaluated at the National Institutes of Health.
| Condition | Intervention |
|---|---|
|
Brain and Central Nervous System Tumors Chordoma Neuroblastoma |
Other: physiologic testing |
| Study Type: | Observational |
| Official Title: | Evaluation of the Natural History of Patients With Tumors of the Central Nervous System |
| Estimated Enrollment: | 3000 |
| Study Start Date: | January 2001 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: Patients receive an initial evaluation by the NCI Neuro-Oncology Branch at the NIH Clinical Center. Patients may choose to end their participation on the study after the initial evaluation or may continue being evaluated at NIH. Generally, patients living in close proximity to the NIH are followed at NIH every 3-6 months. Patients living at a distance from NIH resume standard care with their local physician, but either they are followed periodically at NIH (e.g., if disease progression occurs) or they (and/or their physician) are contacted by the Neuro-Oncology Branch at least every 6 months to generally follow the natural history of the disease and patient outcome.
Patients may undergo any or all of the following procedures at initial or follow-up evaluations: MRI or CT scan, PET scan, blood tests, neurologic exam, and physical exam and history.
PROJECTED ACCRUAL: A total of 3,000 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 1 Year and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Patients with CNS tumors who meet any of the following criteria:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Contacts and Locations| United States, Maryland | |
| NCI - Neuro-Oncology Branch | Recruiting |
| Bethesda, Maryland, United States, 20892-8200 | |
| Contact: Patient Recruitment 301-402-6298 | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: Patient Recruitment 888-NCI-1937 | |
| Study Chair: | Howard A. Fine, MD | NCI - Neuro-Oncology Branch |
More Information
| Study ID Numbers: | CDR0000078676, NCI-01-C-0070 |
| Study First Received: | April 9, 2007 |
| Last Updated: | June 9, 2009 |
| ClinicalTrials.gov Identifier: | NCT00458640 History of Changes |
| Health Authority: | Unspecified |
|
adult anaplastic astrocytoma adult anaplastic meningioma adult anaplastic oligodendroglioma adult brain stem glioma adult craniopharyngioma adult diffuse astrocytoma adult ependymoblastoma adult ependymoma adult giant cell glioblastoma adult medulloblastoma adult meningeal hemangiopericytoma adult myxopapillary ependymoma adult oligodendroglioma adult papillary meningioma adult pilocytic astrocytoma |
adult pineoblastoma adult pineocytoma adult subependymoma adult ependymoma adult gliosarcoma adult central nervous system germ cell tumor adult choroid plexus tumor adult supratentorial primitive neuroectodermal tumor (PNET) adult melanocytic lesion adult grade I meningioma adult grade II meningioma adult grade III meningioma adult mixed glioma childhood mixed glioma recurrent adult brain tumor |
|
Neoplasms by Histologic Type Neuroectodermal Tumors, Primitive Astrocytoma Neoplasms, Nerve Tissue Nervous System Diseases Central Nervous System Neoplasms Chordoma Neuroblastoma Neuroectodermal Tumors |
Neoplasms Neoplasms by Site Neoplasms, Germ Cell and Embryonal Glioma Neoplasms, Neuroepithelial Nervous System Neoplasms Neuroectodermal Tumors, Primitive, Peripheral Neoplasms, Glandular and Epithelial |